Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Hatch-Waxman Safe Harbor Could Get Supreme Court Review

This article was originally published in The Pink Sheet Daily

Executive Summary

High court invites the Solicitor General to submit a brief after GlaxoSmithKline seeks review of a Federal Circuit finding that the safe harbor provision barring infringement claims only pertains to actions to obtain generic approvals; the ruling held GSK’s participation in a study on immunization schedules infringed Classen patents.


Related Content

Hatch-Waxman Safe Harbor Ruling Wrong In GSK Case, Solicitor General Says, But Should Not Be Reviewed
Hatch-Waxman “Safe Harbor” Could Face Two-Front Battle In Supreme Court
Hatch-Waxman “Safe Harbor” Ruling Threatens Compound Patents, Momenta Says
Manufacturing Patents In Peril After Court Extends Hatch-Waxman “Safe Harbor”
Bilski's Broad Sweep: Federal Circuit Says Vaccination Schedule Analysis Is Patentable


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts